纪念斯隆-凯特琳癌症中心

Join Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center (MSK), today for his presentation on preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults wwith advanced pancreatic, colorectal, and non-small cell lung cancer. Learn more: https://bit.ly/4d6Npn9

We'd like to congratulate Dr. Alan Ho on his new role as Chief of the Head and Neck Oncology Service within the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Learn more about Dr. Ho: https://bit.ly/4e0Gltv

Join Dr. Alan Ho, a head and neck oncologist at Memorial Sloan Kettering Cancer Center (MSK), today at the 2024 European Society for Medical Oncology Congress for his poster session on a phase 2 study evaluating the efficacy of HB-200 in patients with detectable TTMV-HPV DNA after definitive treatment for HPV16 + HNSCC. Learn more: https://bit.ly/47nXGdB

Join Dr. Winston Wong, a head and neck oncologist at Memorial Sloan Kettering Cancer Center (MSK), on Saturday, September 14 at the 2024 European Society for Medical Oncology Congress for his poster session on phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Learn more: https://bit.ly/47nXGdB

Join Dr. Claire Friedman, a gynecologic medical oncologist at Memorial Sloan Kettering Cancer Center (MSK), on Saturday, September 14 at the 2024 European Society for Medical Oncology Congress for her poster session on phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC). Learn more: https://bit.ly/47nXGdB

Join Joe Lengfellner, Senior Director for Clinical Research Informatics & Technology at Memorial Sloan Kettering Cancer Center (MSK), for a panel session at the DPharm Conference in Philadelphia on September 17-18. He will discuss how to “make eSource EHR a reality," and share insights about clinical research-focused innovation taking place at MSK. Learn more and register here: https://bit.ly/47qhb53

Join Dr. Alexander Drilon, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center (MSK) on Saturday, September 14 as he discusses phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid #tumors. Learn more: https://bit.ly/3Zphz1R

Memorial Sloan Kettering Cancer Center (MSK) surgeon-scientists recently published results from a series of patients who received open bilateral primary retroperitoneal lymph node dissection (RPLND) over a 10-year period. “Our experience shows that primary RPLND provides patients with a safe and highly effective alternative to chemotherapy or radiation for low-volume pure seminoma that has metastasized to the retroperitoneum,” says Dr. Richard Matulewicz, a urologic surgeon at MSK. Here, Dr. Matulewicz discusses MSK’s experience with RPLND for select patients with low-volume seminoma metastatic to the retroperitoneum, as well as MSK’s pioneering work developing the MSK microRNA assay for men with germ cell tumors.

Experts at Memorial Sloan Kettering Cancer Center (MSK) and MSK Kids help patients, like Armani who was diagnosed with sickle cell disease (SCD), feel supported through shared culture and language. SCD is most common in people of African American and Hispanic/Latino descent. MSK reflects the diversity of nationalities and ethnicities in New York and throughout the world. MSK Kids sees patients from nearly 70 countries and its staff speaks more than 25 languages. Many MSK physicians like Dr. Maria Cancio, a hematologist-oncologist, are bilingual and can communicate with patients in their preferred language. “Armani and his mom are fully fluent in English and Spanish, but it’s nice to have that special connection with someone who understands your culture and is part of your village,” says Dr. Cancio, who is of Puerto Rican descent. Armani received a blood marrow transplant and Dr. Cancio was able to guide Armani and his mother through the surgery and recovery process. Today, Armani is thriving, and his mother says she is grateful for the excellent care he received at MSK. Learn more: https://bit.ly/47omzpi

Join Memorial Sloan Kettering Cancer Center (MSK) sarcoma specialist Dr. Evan Rosenbaum today at the 2024 European Society for Medical Oncology Congress as he discusses a phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma. #ESMO24 Learn more: https://bit.ly/3TufcXF